Trials in EGFR Mutated NSCLC: Mariposa2 and Laura- 2024 Leading Developments in Lung Cancer

Trials in EGFR Mutated NSCLC: Flaura2 and Mariposa- 2024 Leading Developments in Lung CancerПодробнее

MARIPOSA-2: amivantamab + chemo (± lazertinib) vs chemo in EGFR-mutated NSCLC post-osimertinibПодробнее

Q & A with EGFR-Mutant Lung Cancer Experts | 2024 Living with EGFR-Mutant Lung Cancer Patient ForumПодробнее

LAURA Trial - Osimertinib as Consolidation in non-small cell lung cancer.Подробнее

Lung Cancer ESMO 2024 Highlights: Key Studies Discussed LAURA, MARIPOSA, MARIPOSA-2, ADRIATICПодробнее

TAGRISSO - 84% Reduction in Disease in Stage III EGFR-Mutated Lung Cancer: LAURA TrialПодробнее

LAURA trial: a new standard of care in unresectable stage III EGFRm NSCLCПодробнее

LAURA: osimertinib and chemoradiotherapy in stage III EGFR-m NSCLCПодробнее

Treatment Updates: EGFR-Mutant Lung Cancer | 2024 Living with EGFR-Mutant Lung Cancer Patient ForumПодробнее

FLAURA Trial Demonstrates Efficacy in EGFR-Positive Lung CancerПодробнее

EGFR-Mutant Lung Cancer & Treatment Options | 2023 Living with EGFR-Mutant Lung Cancer Patient ForumПодробнее

MARIPOSA: mechanisms of resistance to 1L amivantamab + lazertinib in pts with EGFR-m NSCLCПодробнее

Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLCПодробнее

ADAURA Trial: Tagrisso & Resectable EGFR+ - Leading Developments & Current Questions in Lung CancerПодробнее

Dr. Sequist on Rationale for TATTON Trial in EGFR-Mutant Lung CancerПодробнее

The Two Onc Docs Reflect on Interviewing Dr. Ramalingam About Historic LAURA PlenaryПодробнее